Ind-Swift Laboratories, a Rs.1000 crore plus pharma giant, has received US FDA approval for five active pharmaceutical ingredients (APIs) viz., naratriptan hydrochloride, ropinirole hydrochloride, donenpezil hydrochloride, acamprosate calcium and clarithromycin, manufactured at its Derabassi facility.

The worldwide market for these products is US$5 billion. With this approval the company has entered in the league of Big Pharma majors having multi product approval for its facilities.

The facilities were inspected in mid 2011. The Derabassi facility is already accredited by key accreditation agencies like TGA, MHRA, COS, KFDA and PMDA. With this approval the company will be able to sell its products to US market.

N R Munjal, vice-chairman and managing director, said, “ This multi product approval will give multifold aggression to the sales as we have good presence in US through our US subsidiary and we expect this approval to give additional 50-60 per cent growth in US sales. The company is already supplying three products commercially to the US markets which presently is contributing 3 per cent of the sales and the company expects this figure to reach to 7-8 per cent in next two to three years.”